Goldman Sachs Remains a Buy on Bayer (0P6S)
Goldman Sachs analyst James Quigley maintained a Buy rating on Bayer today and set a price target of €54.50.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quigley covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and Sanofi. According to TipRanks, Quigley has an average return of -9.6% and a 36.08% success rate on recommended stocks.
In addition to Goldman Sachs, Bayer also received a Buy from Barclays’s Charles Pitman CFA in a report issued today. However, on the same day, Jefferies maintained a Hold rating on Bayer (LSE: 0P6S).
0P6S market cap is currently €39.9B and has a P/E ratio of -201.54.
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer: Dose for expansion in PAnTHa study successfully identified
- Bayer reports final results from Phase III PEACE-3 trial of XOFIGO
- Law firms urge judge to delay review of proposed Bayer settlement, Reuters says
- Bayer files false advertising suit against J&J and Janssen Biotech
- 0P6S Earnings Report this Week: Is It a Buy, Ahead of Earnings?
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.